中文名 | 2-(2-氯-4-碘苯氨基)-N-(环丙基甲氧基)-3,4-二氟苯甲酰胺 |
英文名 | 2-(2-Chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide |
别名 | MEK小分子抑制剂(CI-1040) 2-(2-氯-4-碘苯氨基)-N-(环丙基甲氧基)-3,4-二氟苯酰胺 2-(2-氯-4-碘苯氨基)-N-(环丙基甲氧基)-3,4-二氟苯甲酰胺 2-[(2-氯-4-碘苯基)胺]-N-(环丙基甲氧基)-3,4-二氟苯甲胺 -[(2-氯-4-碘苯基)氨基]-N-(环丙基甲氧基)-3,4-二氟-苯甲酰胺 2-[(2-氯-4-碘苯基)氨基]-N-(环丙基甲氧基)-3,4-二氟-苯甲酰胺 |
英文别名 | CI1040 CS-333 Ci-1040 PD184352 PD-184352 CI 1040 (PD184352) 2-[(2-CHLORO-4-IODOPHENYL) AMINO]-N-(CYCLOPROPYLME 2-(2-CHLORO-4-IODOANILINO)-N-(CYCLOPROPYLMETHOXY)-3,4-DIFLUOROBENZAMIDE 2-(2-Chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide 2-[(2-Chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro- |
CAS | 212631-79-3 |
化学式 | C17H14ClF2IN2O2 |
分子量 | 478.66 |
InChI | InChI=1/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24) |
密度 | 1.747±0.06 g/cm3(Predicted) |
熔点 | 166-169°C |
溶解度 | DMSO: ≥ 30 mg/mL |
折射率 | 1.656 |
酸度系数 | -5.58±0.50(Predicted) |
存储条件 | room temp |
外观 | 粉末 |
颜色 | white to tan |
MDL号 | MFCD02683961 |
体外研究 | CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. CI-1040治疗使多重肿瘤细胞,包括结肠26,BX-PC3 胰腺癌,A431 子宫颈癌,HT-29结肠癌, ZR-25-1乳腺癌和SKOV-3 卵巢癌细胞中pMAPK 水平降低。CI-1040治疗不抑制Jun激酶,p38 激酶或Akt的磷酸化作用,这表明CI-1040特定作用于MEK。CI-1040对MAPK活化的抑制阻止细胞周期进程,并诱导G1期阻滞。 CI-1040抑制MEK1的IC50为0.3 μM,比抑制Swiss 3T3细胞中EGF诱导的ERK2活化所需的浓度高15倍。这些结果表明CI-1040通过抑制MKK1活化,而不是通过阻断MKK1活性对细胞发挥作用。2 nM PD184352抑制Swiss 3T3细胞中50%的MKK1活化,而超过100倍浓度的CI-1040在体外抑制MEK1。PD184352也会抑制Raf催化的MEK1磷酸化,而对Raf催化的髓鞘碱性蛋白磷酸化没有作用。与仅用DMSO处理的细胞相比,CI-1040抑制86%甲状腺乳头状癌(PTC)细胞生长,10μM浓度时导致RET/PTC1重排。CI-1040对PTC细胞(BRAF 突变)表现出有效的抑制作用,GI50为52 nM,但是对RET/PTC1重排型活性较低,GI50 为1.1 μM。一项最近的研究表明CI-1040增加CML 急变期细胞系,K562,和初级慢性期CD34+ CML细胞中BMS-214662的凋亡作用。 |
体内研究 | Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. CI-1040口服给药减弱小鼠和人结肠肿瘤异种移植物的生长,具有48-200 mg/kg每剂的广泛剂量范围,但是对P388白血病没有作用。 CI-1040口服给药(300 mg/kg/d)3周后,抑制来自PTC细胞的肿瘤异种移植物,与未处理的(仅载体处理)小鼠相比,使携带BRAF突变型的移植物减少31.3%,携带RET/PTC1重排型的移植物减少47.5%。小鼠用CI-1040处理时,没有观察到毒性作用。乳腺肿瘤对CI-1040和UCN-01的瞬时暴露引起肿瘤细胞体内死亡,并延长对肿瘤再生长的抑制。CI-1040 (25 mg/kg) 和UCN-01 (0.1-0.2 mg/kg)的联合治疗显著减少MDA-MB-231,并很大程度上废除植入无胸腺小鼠的MCF7肿瘤生长,而任何单一治疗都没有显著活性。联合用药引起显著的肿瘤细胞死亡,这与ERK1/2的磷酸化和Ki67与CD31的免疫活性降低相一致。 |
危险品标志 | N - 危害环境的物品 |
风险术语 | 50/53 - 对水生生物有极高毒性,可能对水体环境产生长期不良影响。 |
安全术语 | S60 - 该物质及其容器须作为危险性废料处置。 S61 - 避免释放至环境中。参考特别说明/安全数据说明书。 |
危险品运输编号 | UN 3077 9 / PGIII |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.089 ml | 10.446 ml | 20.892 ml |
5 mM | 0.418 ml | 2.089 ml | 4.178 ml |
10 mM | 0.209 ml | 1.045 ml | 2.089 ml |
5 mM | 0.042 ml | 0.209 ml | 0.418 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!